Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.61 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | XDH | P47989 | 1/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29672835 | 1.00 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1KDM4EXDHADORA2A | |
| SCHEMBL13288408 | 0.83 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1KDM4EADORA2AADORA1 | |
| SCHEMBL21507710 | 0.82 | CLK4 (0.51) | HSP90AA1HSP90AB1KDM4EXDHADORA2A | |
| SCHEMBL1357565 | 0.82 | XDH (0.55) | XDHADORA2AADORA1CTSSCTSK | |
| SCHEMBL30401905 | 0.79 | XDH (0.52) | XDHADORA2AADORA1CTSSCTSK | |
| SCHEMBL20416555 | 0.79 | XDH (0.52) | XDHADORA2AADORA1CTSSCTSK | |
| SCHEMBL27460747 | 0.79 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1KDM4EADORA2AADORA1 | |
| SCHEMBL4277540 | 0.79 | HSP90AA1 (0.71) | HSP90AA1HSP90AB1KDM4EADORA2AADORA1 | |
| SCHEMBL20416722 | 0.79 | XDH (0.55) | XDHADORA2AADORA1CTSSCTSK | |
| SCHEMBL31186635 | 0.79 | XDH (0.55) | XDHADORA2AADORA1CTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-10-09 | — | — | US | disclosed |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | INCYTE CORPORATION | 2025-02-06 | — | — | US | disclosed |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | INCYTE CORPORATION | 2025-01-30 | — | — | US | disclosed |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | INCYTE CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| CN-117903140-A | Imidazopyrimidines and triazolopyrimidines as A2A/A2B inhibitors | 因赛特公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-117500503-A | Combination therapy comprising an A2A/A2B inhibitor, a PD-1/PD-L1 inhibitor and an anti-CD 73 antibody | 因赛特公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-4310082-A2 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | Arcus Biosciences, Inc. (US) | 2024-01-24 | — | — | EP | disclosed |
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | INCYTE CORPORATION (US) | 2024-01-16 | — | — | US | disclosed |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ARCUS BIOSCIENCES, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. | 2018-08-02 | — | — | US | disclosed |
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-7737153-B2 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-06-15 | — | — | US | disclosed |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1562935-B1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| WO-2004039796-A1 | HETEROARYLOXY-SUBSTITUTED PHENYLAMINOPYRIMIDINES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2004-05-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11873304-B2 | Fused pyrimidine derivatives as A2A/A2B inhibitors | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 2283/4885HSP90AB1 1394/4885KDM4E 4580/4885 |
| US-12060433-B2 | CD73 inhibitor and A2A/A2B adenosine receptor inhibitor combination therapy | ADORA2A, ADORA2B, NT5E | HSP90AA1 1536/4885HSP90AB1 1053/4885KDM4E 3788/4885 |
| US-20250059293-A1 | CD73 INHIBITOR AND A2A/A2B ADENOSINE RECEPTOR INHIBITOR COMBINATION THERAPY | ADORA2A, ADORA2B, NT5E | HSP90AA1 1536/4885HSP90AB1 1053/4885KDM4E 3788/4885 |
| US-20250041310-A1 | Combination Therapy Comprising A2A/A2B and PD-1/PD-L1 Inhibitors | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 991/4885HSP90AB1 516/4885KDM4E 3443/4885 |
| US-20060241127-A1 | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors | ROCK1, ROCK2, RHOA | HSP90AA1 686/4885HSP90AB1 676/4885KDM4E 1134/4885 |
| US-20180215730-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 1702/4885HSP90AB1 1130/4885KDM4E 3131/4885 |
| US-10399962-B2 | Azolopyrimidine for the treatment of cancer-related disorders | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 1702/4885HSP90AB1 1130/4885KDM4E 3131/4885 |
| US-20250034153-A1 | TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 2557/4885HSP90AB1 1695/4885KDM4E 4413/4885 |
| US-20250313567-A1 | IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS A2A / A2B INHIBITORS | ADORA2A, ADORA2B, ADORA1 | HSP90AA1 2556/4885HSP90AB1 1865/4885KDM4E 4274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.